Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.59 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP4 | P49662 | 1/20 | 0.37 |
| ▸ | CASP5 | P51878 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1202459 | 1.00 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL1201943 | 1.00 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL10685115 | 0.92 | CHRM5 (0.46) | CHRM5ADRA2CACHEKDM2B | |
| SCHEMBL478537 | 0.79 | CHRM5 (0.39) | CHRM5ADRA2CACHESIGMAR1 | |
| SCHEMBL1201492 | 0.77 | CHRM5 (0.67) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL4580897 | 0.76 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL4579439 | 0.76 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL29117299 | 0.76 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL1201944 | 0.76 | ACHE (0.62) | CHRM5ADRA2CACHECHRM2CHRM4 | |
| SCHEMBL4218768 | 0.76 | CHRM5 (0.59) | CHRM5ADRA2CACHECHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946259-B2 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-03-06 | — | — | US | disclosed |
| US-8598353-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-12-03 | — | — | US | disclosed |
| EP-1863771-B1 | BENZAZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE AS B-SECRETASE INHIBITORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2457901-A1 | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors | High Point Pharmaceuticals, LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-03-17 | — | — | US | disclosed |
| US-7893267-B2 | Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | VTVX HOLDINGS II LLC | 2009-12-31 | — | — | US | disclosed |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | HIGH POINT PHARMACEUTICALS, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326006-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CHRM5 3452/4885ADRA2C 1588/4885ACHE 20/4885 |
| US-20110065713-A1 | Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors | BACE1, BACE2, APP | CHRM5 3277/4885ADRA2C 1996/4885ACHE 27/4885 |
| US-20060223849-A1 | Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors | BACE1, BACE2, APP | CHRM5 3452/4885ADRA2C 1588/4885ACHE 20/4885 |
| US-20140066477-A1 | Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors | BACE1, BACE2, APP | CHRM5 3452/4885ADRA2C 1588/4885ACHE 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.